Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
ALR's Cash to Debt is ranked lower than
88% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ALR: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
ALR' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.13
0.08
1.88
Equity to Asset 0.32
ALR's Equity to Asset is ranked lower than
81% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALR: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
ALR' s Equity to Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.38 Max: 0.77
Current: 0.32
-0.49
0.77
Interest Coverage 0.85
ALR's Interest Coverage is ranked lower than
98% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. ALR: 0.85 )
Ranked among companies with meaningful Interest Coverage only.
ALR' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 0.48 Max: 1.37
Current: 0.85
0.24
1.37
F-Score: 4
Z-Score: 0.87
M-Score: -2.35
WACC vs ROIC
5.77%
1.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.01
ALR's Operating margin (%) is ranked higher than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. ALR: 8.01 )
Ranked among companies with meaningful Operating margin (%) only.
ALR' s Operating margin (%) Range Over the Past 10 Years
Min: -44.13  Med: 2.37 Max: 7.6
Current: 8.01
-44.13
7.6
Net-margin (%) 17.29
ALR's Net-margin (%) is ranked higher than
88% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. ALR: 17.29 )
Ranked among companies with meaningful Net-margin (%) only.
ALR' s Net-margin (%) Range Over the Past 10 Years
Min: -47.2  Med: -2.87 Max: 1.75
Current: 17.29
-47.2
1.75
ROE (%) 17.96
ALR's ROE (%) is ranked higher than
85% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. ALR: 17.96 )
Ranked among companies with meaningful ROE (%) only.
ALR' s ROE (%) Range Over the Past 10 Years
Min: -34.13  Med: -4.43 Max: 0.32
Current: 17.96
-34.13
0.32
ROA (%) 5.87
ALR's ROA (%) is ranked higher than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. ALR: 5.87 )
Ranked among companies with meaningful ROA (%) only.
ALR' s ROA (%) Range Over the Past 10 Years
Min: -15.33  Med: -1.47 Max: 0.52
Current: 5.87
-15.33
0.52
ROC (Joel Greenblatt) (%) 15.42
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. ALR: 15.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -169.25  Med: 9.33 Max: 22.61
Current: 15.42
-169.25
22.61
Revenue Growth (3Y)(%) 2.80
ALR's Revenue Growth (3Y)(%) is ranked lower than
60% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. ALR: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.75 Max: 36.2
Current: 2.8
-8.6
36.2
EBITDA Growth (3Y)(%) -0.60
ALR's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. ALR: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.3  Med: 8.40 Max: 103.3
Current: -0.6
-9.3
103.3
EPS Growth (3Y)(%) 14.50
ALR's EPS Growth (3Y)(%) is ranked higher than
75% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ALR: 14.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.6  Med: 2.60 Max: 75.4
Current: 14.5
-57.6
75.4
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ALR Guru Trades in Q1 2015

Jim Simons 1,266,124 sh (+224.54%)
Mario Gabelli 208,150 sh (+2.49%)
Private Capital 911,238 sh (+1.00%)
Chuck Royce Sold Out
Joel Greenblatt Sold Out
Pioneer Investments Sold Out
Diamond Hill Capital 2,544,479 sh (-4.67%)
John Keeley 1,240,717 sh (-8.03%)
Manning & Napier Advisors, Inc 838,826 sh (-36.13%)
Steven Cohen 49,000 sh (-96.80%)
» More
Q2 2015

ALR Guru Trades in Q2 2015

Steven Cohen 690,500 sh (+1309.18%)
Jim Simons 1,394,724 sh (+10.16%)
Mario Gabelli 218,400 sh (+4.92%)
Private Capital 927,113 sh (+1.74%)
Diamond Hill Capital 2,243,426 sh (-11.83%)
John Keeley 1,045,227 sh (-15.76%)
Manning & Napier Advisors, Inc 682,226 sh (-18.67%)
» More
Q3 2015

ALR Guru Trades in Q3 2015

Mario Gabelli 233,430 sh (+6.88%)
Private Capital 941,823 sh (+1.59%)
John Keeley 974,047 sh (-6.81%)
Diamond Hill Capital 2,058,095 sh (-8.26%)
Steven Cohen 557,400 sh (-19.28%)
Jim Simons 1,113,424 sh (-20.17%)
Manning & Napier Advisors, Inc 531,294 sh (-22.12%)
» More
Q4 2015

ALR Guru Trades in Q4 2015

Diamond Hill Capital 2,306,319 sh (+12.06%)
Mario Gabelli 235,430 sh (+0.86%)
John Keeley 964,189 sh (-1.01%)
Private Capital 930,548 sh (-1.20%)
Jim Simons 878,424 sh (-21.11%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB382.003.14

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Mar 17, 2015

Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown.

From Diamond Hill Capital (Trades, Portfolio)’s Select Fund Q4 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Mario Gabelli Comments on Alere Inc - Nov 21, 2014

Alere Inc. (0.2% of net assets as of September 30, 2014) (ALR - $38.78 - NYSE) is the largest manufacturer of rapid, point-of-care diagnostics in the world. The company has underperformed for the past year, weighed down by manufacturing problems and a heavy debt load from questionable past acquisitions. An activist investor has been publicly pushing the company to improve operations and, after being slow to respond initially, Alere’s Board of Directors forced the company’s founder and CEO to resign on July 1. However, he has now partnered with private equity partners and is seeking to take the company private with an initial bid of $46 per share. Whatever the final outcome is, we believe positive change is in the air for Alere.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Diamond Hill Capital Comments on Alere Inc - Oct 17, 2014

We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Alere Inc

Diamond Hill Capital Comments on Alere Inc
Diagnostic systems provider Alere, Inc. (ALR) declined after installing a new CEO during the quarter, while weathering an unsolicited attempt by the previous CEO to take the company private. Subsequently, the company announced that it would sell its Health Management business in a first sign of the implementation of a new agenda focused on asset sales and debt paydown. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 13.60
ALR's P/E(ttm) is ranked higher than
91% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.30 vs. ALR: 13.60 )
Ranked among companies with meaningful P/E(ttm) only.
ALR' s P/E(ttm) Range Over the Past 10 Years
Min: 9.25  Med: 135.33 Max: 3605
Current: 13.6
9.25
3605
Forward P/E 22.42
ALR's Forward P/E is ranked lower than
71% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.02 vs. ALR: 22.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.05
ALR's P/B is ranked lower than
61% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ALR: 3.05 )
Ranked among companies with meaningful P/B only.
ALR' s P/B Range Over the Past 10 Years
Min: 0.42  Med: 1.64 Max: 3.08
Current: 3.05
0.42
3.08
P/S 2.02
ALR's P/S is ranked higher than
59% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ALR: 2.02 )
Ranked among companies with meaningful P/S only.
ALR' s P/S Range Over the Past 10 Years
Min: 0.52  Med: 1.43 Max: 3.97
Current: 2.02
0.52
3.97
PFCF 73.25
ALR's PFCF is ranked lower than
85% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.68 vs. ALR: 73.25 )
Ranked among companies with meaningful PFCF only.
ALR' s PFCF Range Over the Past 10 Years
Min: 8.51  Med: 20.53 Max: 116.5
Current: 73.25
8.51
116.5
POCF 29.46
ALR's POCF is ranked lower than
69% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.98 vs. ALR: 29.46 )
Ranked among companies with meaningful POCF only.
ALR' s POCF Range Over the Past 10 Years
Min: 4.63  Med: 11.85 Max: 127.08
Current: 29.46
4.63
127.08
EV-to-EBIT 44.76
ALR's EV-to-EBIT is ranked lower than
79% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.25 vs. ALR: 44.76 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 55.05 Max: 683.2
Current: 44.76
-676
683.2
EV-to-EBITDA 17.86
ALR's EV-to-EBITDA is ranked lower than
56% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.20 vs. ALR: 17.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 12.70 Max: 87.3
Current: 17.86
-173.6
87.3
Current Ratio 1.68
ALR's Current Ratio is ranked lower than
71% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ALR: 1.68 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.74 Max: 3.42
Current: 1.68
0.7
3.42
Quick Ratio 1.35
ALR's Quick Ratio is ranked lower than
73% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ALR: 1.35 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.21 Max: 2.89
Current: 1.35
0.46
2.89
Days Inventory 112.27
ALR's Days Inventory is ranked lower than
52% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. ALR: 112.27 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.21  Med: 85.99 Max: 97.53
Current: 112.27
80.21
97.53
Days Sales Outstanding 73.84
ALR's Days Sales Outstanding is ranked higher than
50% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. ALR: 73.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.28  Med: 66.69 Max: 72.77
Current: 73.84
60.28
72.77
Days Payable 59.56
ALR's Days Payable is ranked higher than
51% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. ALR: 59.56 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 44.62  Med: 49.74 Max: 59
Current: 59.56
44.62
59

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.57
ALR's Price/Projected FCF is ranked higher than
66% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.89 vs. ALR: 1.57 )
Ranked among companies with meaningful Price/Projected FCF only.
ALR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.44  Med: 1.06 Max: 6.47
Current: 1.57
0.44
6.47
Price/Median PS Value 1.41
ALR's Price/Median PS Value is ranked lower than
77% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ALR: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
ALR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 0.93 Max: 2.82
Current: 1.41
0.36
2.82
Price/Graham Number 3.23
ALR's Price/Graham Number is ranked lower than
61% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ALR: 3.23 )
Ranked among companies with meaningful Price/Graham Number only.
ALR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.23  Med: 1.15 Max: 5.82
Current: 3.23
0.23
5.82
Earnings Yield (Greenblatt) (%) 2.20
ALR's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ALR: 2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.50 Max: 3.2
Current: 2.2
0.1
3.2

More Statistics

Revenue(Mil) $2236
EPS $ 3.87
Beta0.52
Short Percentage of Float4.63%
52-Week Range $31.96 - 55.99
Shares Outstanding(Mil)86.26

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 2,521 2,575
EPS($) 2.36 2.35
EPS without NRI($) 2.36 2.35

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:IM5.Germany,
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a strong commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to better manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcome
» More Articles for ALR

Headlines

Articles On GuruFocus.com
The Transformation in Alere May 22 2015 
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 
Mario Gabelli’s Asset Fund Q3 2014 Commentary Nov 21 2014 
Cohen Has Busy Third Quarter Nov 19 2014 
Diamond Hill Capital Comments on Alere Inc Oct 17 2014 
Diamond Hill Select Fund Third Quarter 2014 Commentary Oct 17 2014 

More From Other Websites
Alere–Abbott Labs Is a Large, Strategic Deal for Arbitrageurs Feb 13 2016
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alere, Inc. and... Feb 12 2016
ALERE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Alere Inc. (ALR) Over... Feb 10 2016
The Alere-Abbott Labs Merger: Understanding the Alere Side Feb 09 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alere Inc. of an Investigation... Feb 09 2016
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alere, Inc. and... Feb 08 2016
INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors... Feb 08 2016
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal... Feb 08 2016
Finding Value in These Names -- Agilent Technologies, Exact Sciences, Thermo Fisher Scientific, and... Feb 08 2016
Top 4 BioPharma Movers of the Week Feb 06 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alere Inc. of an Investigation in... Feb 05 2016
ALERE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Alere Inc. (ALR) Over... Feb 04 2016
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of... Feb 04 2016
​Alere executives stand to reap $24M in payouts with Abbott buyout Feb 04 2016
Rationale for the Alere–Abbott Laboratories Merger Feb 04 2016
Abbott Labs Beefs Up Its Diagnostics Portfolio with Alere Feb 04 2016
Harwood Feffer LLP Announces Investigation of Alere Inc. Feb 03 2016
EKF Diagnostics kitchen-sinking will drive break-even 'by April' Feb 03 2016
Abbott Labs to Boost Diagnostics Business with Alere Buyout Feb 02 2016
CEMI: Zika Could Be Seamless Fit to CEMI's Fever Portfolio Feb 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK